Evidence map›Paper›PMID 32641824›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2020

PCP4/PEP19 downregulates neurite outgrowth via transcriptional regulation of Ascl1 and NeuroD1 expression in human neuroblastoma M17 cells.

Ikumi Kitazono, Taiji Hamada, Takuya Yoshimura, Mari Kirishima, Seiya Yokoyama, Toshiaki Akahane, Akihide Tanimoto

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Transcriptional consequences of trisomy 21 on neural induction.Frontiers in cellular neuroscience · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ikumi KitazonoDepartment of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Taiji HamadaDepartment of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Takuya YoshimuraDepartment of Oral and Maxillofacial Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Mari KirishimaDepartment of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Seiya YokoyamaDepartment of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Toshiaki AkahaneDepartment of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Akihide TanimotoDepartment of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. akit09@m3.kufm.kagoshima-u.ac.jp.ORCID http://orcid.org/0000-0001-7508-1624
Kagoshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purkinje cell protein 4/peptide 19 (PCP4/PEP19) is 7.6 kDa peptide originally found in Purkinje cells. PCP4/PEP19 is a differentiation maker of Purkinje cells, where it functions as an antiapoptotic factor. Cerebral neuronal cells also express PCP4/PEP19, which may be related to neuronal cell survival. However, evidence suggests that PCP4/PEP19 may also be involved in neuronal differentiation. Here, we investigated the effects of PCP4/PEP19 expression on neuronal differentiation by analyzing neurite outgrowth, and expression of neuronal differentiation markers in cultured human neuroblastoma M17 cells. When PCP4/PEP19 expression was reduced by siRNA-mediated knockdown, neurite outgrowth was significantly increased. Among many differentiation markers tested, expression of NeuroD1 was increased, while that of Ascl1 was decreased upon PCP4/PEP19 knockdown. Furthermore, luciferase reporter assays revealed that PCP4/PEP19 knockdown upregulated NeuroD1 and downregulated Ascl1 expression, at the transcriptional level. These results suggest a new function of PCP4/PEP19, which suppresses neurite outgrowth and neuronal differentiation through the regulation of NeuroD1 and Ascl1 expression in M17 cells. Furthermore, immunohistochemical studies showed that PCP4/PEP19 localizes in the nuclei of human neuroblastoma cells. Therefore, PCP4/PEP19 may also be an intranuclear negative regulator of neuronal differentiation and may thus be a potential therapeutic target to promote cellular differentiation in human neuroblastoma.

Indexed as

Nerve Tissue ProteinsNeuronal OutgrowthAdultAgedBasic Helix-Loop-Helix ProteinsCell Line, TumorCell ProliferationChildChild, PreschoolDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansInfantInfant, NewbornMaleASCL1 protein, humanBasic Helix-Loop-Helix ProteinsNerve Tissue ProteinsNEUROD1 protein, humanPCP4 protein, humanRecombinant Fusion Proteins

Identifiers

PMID32641824
OpenAlexW3042082363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.